Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Affimed Ord Shs
(NQ:
AFMD
)
3.160
-0.050 (-1.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Affimed Ord Shs
< Previous
1
2
3
Next >
Affimed to Present at the Cantor Global Healthcare Conference 2024
September 10, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Reports Second Quarter 2024 Financial Results & Business Update
September 05, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Appoints Shawn M. Leland as Chief Executive Officer
September 03, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
August 29, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Reports First Quarter 2024 Financial Results & Business Update
June 12, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
June 05, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
June 01, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
May 29, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Annual General Meeting of Shareholders
May 28, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
May 23, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
May 14, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
April 24, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Reports 2023 Financial Results and Operational Progress
March 28, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
March 21, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces 1-for-10 Reverse Stock Split
March 06, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
January 08, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Leadership Change and Organizational Restructuring
January 08, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
January 03, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
December 11, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
December 11, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
December 04, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
November 14, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
November 09, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
November 07, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
November 03, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
November 02, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Participate in Upcoming Investor Conferences
November 01, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Listing Transfer to Nasdaq Capital Markets
October 04, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
September 27, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Present at the Cantor Global Healthcare Conference 2023
September 21, 2023
From
Affimed N.V.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.